How to Use Red Light Therapy for Migraines

Red light therapy for migraines, more precisely called photobiomodulation, involves applying specific wavelengths of red or near-infrared light to the head, neck, or face to reduce headache frequency and intensity. Early clinical trials show measurable reductions in migraine pain and episode frequency compared to sham treatment, but the research is still limited, and details like wavelength, placement, and timing make the difference between a potentially useful tool and wasted money.

What the Clinical Evidence Shows So Far

The most relevant evidence comes from randomized trials testing low-level laser therapy and LED-based photobiomodulation against sham devices in headache patients. A systematic review of these trials found that in a 50-person study comparing active low-level laser therapy to sham over ten sessions across three weeks, the laser group showed significant improvements two months after treatment: pain scores dropped, headache episode frequency fell substantially, and the duration of individual episodes shortened, all by statistically significant margins compared to participants who received the sham device.¹

A broader systematic review of photobiomodulation for chronic pain conditions, including neuropathies and musculoskeletal pain, found that most trials demonstrated significant pain reduction and that adverse events were rare, reinforcing the method’s safety profile. However, the review also flagged a recurring problem across the field: the technical parameters used in different studies vary so much that standardizing recommendations is difficult.² Reviewers of light therapy for chronic migraine have echoed this concern, noting that while the results are promising, sample sizes remain small and more extensive trials are needed before anyone can call this a proven treatment.³

What this means practically: red light therapy for migraines is not yet at the level of evidence behind, say, CGRP-targeting medications or even Botox injections. It sits in the “encouraging early results, needs bigger trials” category. That said, its safety profile is strong enough that trying it alongside conventional treatments carries minimal risk for most people.

How Photobiomodulation Affects Migraine Biology

The proposed mechanism ties into several processes that go wrong during a migraine. Research indicates that photobiomodulation enhances mitochondrial respiration, boosts cellular energy production (ATP), helps restore the balance of reactive oxygen species, and modulates nitric oxide signaling. Collectively, these effects improve blood flow in the brain and help regulate the coupling between neural activity and vascular response.⁴ Since migraines involve disrupted blood vessel behavior and neuronal excitability, shoring up these systems could theoretically make attacks less likely to ignite or less severe when they do.

One area that gets a lot of attention in migraine circles is CGRP, the neuropeptide that plays a central role in migraine pain signaling. Interestingly, a rat study testing infrared laser therapy and LED exposure found that while the laser triggered the release of substance P (another pain-related neuropeptide), it did not change CGRP secretion.⁵ This is worth noting because it suggests the benefits of red light therapy for migraines probably do not come from directly suppressing CGRP in the way that monoclonal antibody drugs do. The pathway appears to be different, centered more on cellular energy and blood flow regulation than on blocking a single pain molecule.

Choosing a Wavelength and Where to Put It

Not all red light is created equal when it comes to reaching migraine-relevant structures. Standard red light in the 620 to 670 nanometer range penetrates tissue only shallowly, making it suitable for surface-level targets like the skin over the temples, the muscles at the back of the neck, or trigger points along the jaw. For anything deeper, including attempts to reach brain tissue directly through the skull, you need near-infrared wavelengths. The two most commonly used for transcranial photobiomodulation are 810 nm and 1064 nm.⁶

Where you place the device depends on what you are trying to target. Clinical protocols for headache have used two main approaches:

Transcranial application: Near-infrared LEDs or laser diodes placed against the forehead, temples, or the back of the skull. This aims to get photons through bone and into cortical brain tissue, targeting the neural circuits involved in migraine generation.
Peripheral application: Red or near-infrared light applied to the neck, jaw, and upper shoulder muscles. This targets muscle tension, trigger points, and superficial nerve branches that feed into headache pain, especially in tension-type and cervicogenic headaches that frequently coexist with migraine.

Many of the headache trials have used devices applied directly to the head or face rather than whole-body light panels. A panel across the room delivers far less energy to the scalp than a device held flush against it. If your goal is transcranial effects, contact or near-contact placement matters.

Pulsed Light Versus Continuous

Consumer red light devices typically emit continuous-wave light, meaning the LEDs stay on at a steady intensity. Some newer devices offer pulsed mode, where the light flickers on and off at a set frequency. Research comparing the two suggests these are not interchangeable. A study using near-infrared LEDs on healthy subjects found that pulsed light significantly activated alpha brainwave rhythms, and that operating at different frequencies could induce specific brainwave patterns.⁷ A separate study on transcranial photobiomodulation confirmed that pulsed delivery produced better cognitive effects and more pronounced changes in brain electrical activity than continuous-wave light under certain conditions.⁸

For migraine specifically, this is relevant because cortical excitability plays a role in triggering attacks, particularly the spreading wave of depolarization called cortical spreading depression. If pulsed near-infrared light can modulate brainwave activity more effectively than continuous light, it could theoretically influence this excitability threshold. That said, no head-to-head trial has yet tested pulsed versus continuous specifically in migraine patients, so this remains a reasonable inference rather than a proven recommendation. If your device offers pulsed mode, it is worth experimenting with, but continuous-wave devices are not useless.

Why Timing Matters More Than You Might Think

Here is a fact that trips up many people: using red light during an active migraine attack may actually make things worse. A clinical study found that visual exposure to white and red light intensified pain in migraine patients during acute attacks, while green light produced a markedly lesser exacerbation.⁹ This is not about photobiomodulation devices specifically; it reflects how the migraine brain processes different wavelengths of light when it is already in crisis mode. But it means that shining a red-wavelength device at your face while you are in the middle of an attack could amplify photophobia-driven pain.

The successful headache trials used photobiomodulation as a preventive strategy, delivering sessions on a regular schedule between attacks rather than as an acute rescue treatment. The trial in the systematic review, for instance, ran ten sessions over three weeks and then measured outcomes two months later.¹ The clinical benefit appeared to build over time, not to provide immediate relief during an episode. If you are going to try this approach, think of it like taking a daily preventive medication: the goal is fewer and milder attacks over weeks, not pain relief in the moment.

Green Light as an Unexpected Contender

While most conversations about “red light therapy” focus on red and near-infrared wavelengths, green light in the 520 to 530 nanometer range has arguably produced the most striking migraine-specific results so far. In a clinical trial exposing migraine patients to green LED light for one to two hours per day over ten weeks, headache days per month dropped from an average of about 18 to about 7, a reduction of roughly 60%. Pain intensity scores during the headache phase also fell sharply, from about 8 out of 10 to about 3.¹⁰

The mechanism is different from red or near-infrared photobiomodulation. Green light therapy works through the eyes, not through transcranial penetration. It appears to modulate pain pathways via retinal signaling rather than by directly boosting mitochondrial function in neurons. This also explains why the green light approach uses ambient exposure: patients sit in a room illuminated by a green LED light strip or lamp, rather than holding a device against their head. It is a fundamentally different treatment modality that happens to share the “light therapy” label.

For someone with frequent migraines who wants to try light-based approaches, this raises an interesting practical question. Green light therapy requires nothing more than a specific-wavelength LED bulb or strip used in a dark room for one to two hours daily, and it has a stronger migraine-specific evidence base than red or near-infrared transcranial devices at this point. It is also the only light color shown to not worsen pain during an active attack.⁹ The two approaches are not mutually exclusive, but if you are choosing one to start with, the green light data is hard to ignore.

Safety and Who Should Be Cautious

The safety profile of light therapy devices is generally reassuring. A review of ocular safety concluded that light therapy is safe for the eyes in physically healthy people who are not taking photosensitizing medications. The review did note that people with preexisting eye abnormalities or increased light sensitivity may need more caution, though even theoretical concerns did not support strict contraindications.¹¹ A separate systematic review looking specifically at repeated low-level red light exposure found no cases of permanent vision loss. The most common side effect was a temporary afterimage that resolved within six minutes in the studies that measured it. Two case reports described a patient who experienced a reversible decline in visual sharpness and some changes on retinal imaging, both of which completely resolved within four months of stopping treatment.¹²

People who should approach with extra caution include those taking medications known to increase photosensitivity (certain antibiotics, retinoids, some psychiatric medications), those with retinal conditions or a history of macular degeneration, and anyone who has had recent eye surgery. If you are using a transcranial near-infrared device, the light does not enter the eye directly, so ocular concerns are less relevant. But for green light therapy, which works through visual exposure, eye health matters more.

Across the broader chronic pain literature, the incidence of adverse events from photobiomodulation was low enough that reviewers consistently flagged it as one of the treatment’s strengths.² The main risk is not harm from the device itself but wasted time and money if the wrong parameters are used, or if someone delays proven migraine treatments in favor of an experimental one.

Putting Together a Practical Protocol

No official clinical guidelines exist for red light therapy for migraines yet, so any home protocol is assembled from the parameters used in published trials and the broader photobiomodulation literature. Here is what the available evidence points toward:

Wavelength: 810 nm near-infrared for transcranial use, 620 to 670 nm red for peripheral targets like neck muscles and temples. If pursuing green light therapy for ambient visual exposure, 520 to 530 nm.
Placement: Direct contact or near-contact with the skin for red and near-infrared devices. Forehead, temples, and the suboccipital region at the base of the skull are the most commonly targeted areas. For green light, ambient room exposure with eyes open.
Session length: Clinical trials have used sessions ranging from about 10 to 30 minutes for direct photobiomodulation devices. Green light exposure trials used one to two hours per day.
Frequency: Most headache trials delivered sessions three or more times per week for at least three weeks. Benefits in the primary headache trial were measured at two months, suggesting a cumulative effect that builds over several weeks of regular use.
Approach: Preventive, not acute. Use sessions between attacks on a regular schedule rather than pulling out the device during a migraine.

One of the consistent frustrations in this field is that consumer devices vary enormously in actual light output, and many do not list power density or energy dose in their marketing. A dim red LED mask marketed for skincare delivers a fraction of the energy used in clinical trials. If you are serious about trying photobiomodulation for migraines, look for devices that specify their power output in milliwatts per square centimeter and compare that to parameters used in published research. The difference between a device that delivers a clinical dose and one that glows reassuringly but does almost nothing is not something you can judge by looking at it.

The Standardization Problem

The biggest obstacle to giving clean, confident advice on how to use red light therapy for migraines is not that the biology is implausible or that the trials are negative. The problem is that almost every study uses different parameters: different wavelengths, different power densities, different session durations, different pulse frequencies, different anatomical targets. When reviewers try to synthesize these studies, they repeatedly note that this heterogeneity in technical parameters makes it nearly impossible to standardize results or identify optimal treatment protocols.² Modeling work on transcranial delivery has tried to address this by simulating how photons at different wavelengths distribute through actual brain tissue, finding that even skull thickness and tissue composition vary enough between individuals to significantly change how much light reaches targeted brain regions.⁶

This means that even if photobiomodulation works for migraines in principle, there could be a meaningful difference in results between a thin-skulled person using a 1064 nm device pressed firmly against the forehead and a thick-skulled person using the same device held slightly away. Personalized dosing is where the research is heading, but it is not where consumer products are yet. For now, the honest advice is to try the parameters closest to what worked in trials, be consistent for at least four to six weeks before judging results, and keep your expectations calibrated to “potentially useful add-on” rather than “standalone cure.”

1
PubMed Central. Photobiomodulation for the Treatment of Primary Headache: Systematic Review of Randomized Clinical Trials
2
Frontiers in Integrative Neuroscience. Photobiomodulation in chronic pain: a systematic review of randomized clinical trials
3
Current Pain and Headache Reports. Light Therapy in Chronic Migraine
4
PubMed. Photobiomodulation and Migraine: Mechanisms and Therapeutic Potential
5
PubMed. Low-level laser therapy and light-emitting diode effects in the secretion of neuropeptides SP and CGRP in rat skin
6
PubMed Central. Noninvasive prediction of photon fluence rate in targeted brain regions for personalized transcranial photobiomodulation dosage
7
PubMed Central. Effect of Near-Infrared Pulsed Light on the Human Brain Using Electroencephalography
8
PubMed. Pulsed transcranial photobiomodulation generates distinct beneficial neurocognitive effects compared with continuous wave transcranial light
9
Frontiers in Pain Research. Mechanisms and clinical application of photobiomodulation in pain therapy: a mini review
10
PubMed Central. Evaluation of Green Light Exposure on Headache Frequency and Quality of Life in Migraine Patients: A Preliminary One-way Cross-over Clinical Trial
11
PubMed. Light therapy: is it safe for the eyes?
12
PubMed. Safety of repeated low-level red-light therapy for myopia: A systematic review